The role of advanced glycation in the pathogenesis of diabetic retinopathy. (Q35166467)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

The role of advanced glycation in the pathogenesis of diabetic retinopathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Alan W Stitt

1 reference

6 August 2017

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

Experimental and Molecular Pathology

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

95-108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Retinal neurodegeneration: early pathology in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Molecular mechanisms of vascular permeability in diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Vascular lesions in diabetes are distributed non-uniformly within the retina

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocin-induced diabetes in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Vascular filtration function in galactose-fed versus diabetic rats: the role of polyol pathway activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Protein kinase C and the development of diabetic vascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pathophysiology of oxidative stress in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pathways of Formation of Glycoxidation Products during Glycation of Collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Glycoxidation and lipoxidation in atherogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The AGE-receptor in the pathogenesis of diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The biology of the receptor for advanced glycation end products and its ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Receptors for proteins modified by advanced glycation endproducts (AGE)--their functional role in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products and their recognition by macrophage and macrophage-derived cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3'-kinase to Ras by redox stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation endproducts and diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Relevance of oxidative and carbonyl stress to long-term uremic complications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products in adolescents and young adults with diabetic angiopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Localization in human diabetic peripheral nerve of N ε -carboxymethyllysine-protein adducts, an advanced glycation endproduct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The effect of advanced glycation end-product formation upon cell-matrix interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Increased serum levels of advanced glycation end-products and diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Differential accumulation of advanced glycation end products in the course of diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

In vitro and in vivo alterations of enzymatic glycosylation in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Growth modulation of retinal microvascular cells by early and advanced glycation products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Angiogenic Effects of Advanced Glycation End Products of the Maillard Reaction on Cultured Human Umbilical Cord Vein Endothelial Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products induce angiogenesis in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Inhibition of angiogenesis on glycated collagen lattices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation alters expression of the 67kDa laminin receptor in retinal microvascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

High glucose and advanced glycation end products induce phospholipid hydrolysis and phospholipid enzyme inhibition in bovine retinal pericytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation endproducts accelerate calcification in microvascular pericytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Nitric oxide, advanced glycation end products, and uremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Inhibition of nitric oxide synthase activity by early and advanced glycation end products in cultured rabbit proximal tubular epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Glucose, VEGF-A, and diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Regulation of vascular endothelial growth factor expression by advanced glycation end products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Advanced glycation end products increase retinal vascular endothelial growth factor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Increased retinal endothelial cell monolayer permeability induced by the diabetic milieu: role of advanced non-enzymatic glycation and polyol pathway activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pathogenetic potential of leukocytes in diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Atherogenesis and advanced glycation: promotion, progression, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Chelating activity of advanced glycation end-product inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-4800%2803%2900035-2

10.1016/S0014-4800(03)00035-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12834631%20AND%20SRC:MED&resulttype=core&format=json